Methods	Randomised, double blind, parallel group, no obvious enriched enrolment. Initial dose titration before fixed dose (13 weeks in total)
Participants	Pain persisting for at least 3 months after healing of herpes zoster skin rash, with average daily pain score of at least 40 mm/100 mm. Mean age 70 years, 54% male
Interventions	Pregabalin 150 mg daily, n = 86 Pregabalin 300 mg daily, n = 89 Pregabalin 600 mg daily, n = 97 Placebo daily, n = 97
Outcomes	Proportion of patients with ≥ 30% or ≥ 50% decrease in mean pain score between endpoint and baseline, and other outcomes
Notes	Oxford quality score: R1, D1, W1 = 3/5 Pfizer sponsored
Risk of bias
Item	Authors’ judgement	Description
Adequate sequence generation?	Unclear	Stated to be randomised
Allocation concealment?	Unclear	Not described
Blinding? All outcomes	Unclear	Stated to be double blind